292 related articles for article (PubMed ID: 6850628)
1. Use of uridine rescue to enhance the antitumor selectivity of 5-fluorouracil.
Klubes P; Cerna I
Cancer Res; 1983 Jul; 43(7):3182-6. PubMed ID: 6850628
[TBL] [Abstract][Full Text] [Related]
2. Uridine rescue from the lethal toxicity of 5-fluorouracil in mice.
Klubes P; Cerna I; Meldon MA
Cancer Chemother Pharmacol; 1982; 8(1):17-21. PubMed ID: 6178524
[TBL] [Abstract][Full Text] [Related]
3. High-dose 5-fluorouracil with delayed uridine "rescue" in mice.
Martin DS; Stolfi RL; Sawyer RC; Spiegelman S; Young CW
Cancer Res; 1982 Oct; 42(10):3964-70. PubMed ID: 7104997
[TBL] [Abstract][Full Text] [Related]
4. Modulation of 5-fluorouracil host-toxicity and chemotherapeutic efficacy against human colon tumors by 5-(Phenylthio)acyclouridine, a uridine phosphorylase inhibitor.
Al Safarjalani ON; Rais R; Shi J; Schinazi RF; Naguib FN; el Kouni MH
Cancer Chemother Pharmacol; 2006 Nov; 58(5):692-8. PubMed ID: 16528530
[TBL] [Abstract][Full Text] [Related]
5. Kinetic alterations induced by 5-fluorouracil in bone marrow, intestinal mucosa, and tumor.
Myers CE; Young RC; Chabner BA
Cancer Res; 1976 May; 36(5):1653-8. PubMed ID: 1268826
[TBL] [Abstract][Full Text] [Related]
6. Comparison of 5-fluorouracil and ftorafur. II. Therapeutic response and development of resistance in murine tumors.
Garibjanian BT; Johnson RK; Kline I; Vadlamudi S; Gang M; Venditti JM; Goldin A
Cancer Treat Rep; 1976 Sep; 60(9):1347-61. PubMed ID: 797450
[TBL] [Abstract][Full Text] [Related]
7. In vivo enhancement of 5-fluorouracil cytotoxicity to AKR leukemia cells by thymidine in mice.
Santelli G; Valeriote F
J Natl Cancer Inst; 1978 Sep; 61(3):843-7. PubMed ID: 278862
[TBL] [Abstract][Full Text] [Related]
8. Potent combination therapy for human breast tumors with high doses of 5-fluorouracil: remission and lack of host toxicity.
Al Safarjalani ON; Rais R; Naguib FN; el Kouni MH
Cancer Chemother Pharmacol; 2012 Jun; 69(6):1449-55. PubMed ID: 22373605
[TBL] [Abstract][Full Text] [Related]
9. Comparison of pharmacokinetics of 5-fluorouracil and 5-fluorouracil with concurrent thymidine infusions in a Phase I trial.
Kirkwood JM; Ensminger W; Rosowsky A; Papathanasopoulos N; Frei E
Cancer Res; 1980 Jan; 40(1):107-13. PubMed ID: 7349890
[TBL] [Abstract][Full Text] [Related]
10. Intratumoral injection of thymidine: enhancement of the antitumor activity and incorporation of 5-fluorouracil into tumor RNA in a murine tumor system.
Matsuoka H; Masuda H; Maehara Y; Sugimachi K; Inokuchi K
Cancer Treat Rep; 1986 Jul; 70(7):851-7. PubMed ID: 3719577
[TBL] [Abstract][Full Text] [Related]
11. Tumor-selective metabolism of 5-fluoro-2'-deoxycytidine coadministered with tetrahydrouridine compared to 5-fluorouracil in mice bearing Lewis lung carcinoma.
Boothman DA; Briggle TV; Greer S
Cancer Res; 1987 May; 47(9):2354-62. PubMed ID: 2952263
[TBL] [Abstract][Full Text] [Related]
12. 5-Fluorouracil incorporation into DNA of CF-1 mouse bone marrow cells as a possible mechanism of toxicity.
Schuetz JD; Wallace HJ; Diasio RB
Cancer Res; 1984 Apr; 44(4):1358-63. PubMed ID: 6704957
[TBL] [Abstract][Full Text] [Related]
13. Relationship between antitumor effect and metabolites of 5-fluorouracil in combination treatment with 5-fluorouracil and guanosine in ascites sarcoma 180 tumor system.
Iigo M; Kuretani K; Hoshi A
Cancer Res; 1983 Dec; 43(12 Pt 1):5687-94. PubMed ID: 6640523
[TBL] [Abstract][Full Text] [Related]
14. Clinical pharmacological studies of concurrent infusion of 5-fluorouracil and thymidine in treatment of colorectal carcinomas.
Au JL; Rustum YM; Ledesma EJ; Mittelman A; Creaven PJ
Cancer Res; 1982 Jul; 42(7):2930-7. PubMed ID: 6211226
[TBL] [Abstract][Full Text] [Related]
15. Biochemical and pharmacologic study of therapeutic synergism with cyclophosphamide plus methotrexate in murine L1210 leukemia.
Klubes P; Cerna I
Cancer Treat Rep; 1981; 65(1-2):107-14. PubMed ID: 7226161
[TBL] [Abstract][Full Text] [Related]
16. Dissociation of 5-fluorouracil-induced DNA fragmentation from either its incorporation into DNA or its cytotoxicity in murine T-lymphoma (S-49) cells.
Parker WB; Kennedy KA; Klubes P
Cancer Res; 1987 Feb; 47(4):979-82. PubMed ID: 3802103
[TBL] [Abstract][Full Text] [Related]
17. Modulation of 5-fluorouracil-induced toxicity in mice with interferon or with the interferon inducer, polyinosinic-polycytidylic acid.
Stolfi RL; Martin DS; Sawyer RC; Spiegelman S
Cancer Res; 1983 Feb; 43(2):561-6. PubMed ID: 6184150
[TBL] [Abstract][Full Text] [Related]
18. Effect of 3-deazauridine on the metabolism, toxicity, and antitumor activity of azacitidine in mice bearing L1210 leukemia sensitive and resistant to cytarabine.
Li ZR; Campbell J; Rustum YM
Cancer Treat Rep; 1983 Jun; 67(6):547-54. PubMed ID: 6190558
[TBL] [Abstract][Full Text] [Related]
19. Phase I and pharmacokinetic studies of high-dose uridine intended for rescue from 5-fluorouracil toxicity.
Leyva A; van Groeningen CJ; Kraal I; Gall H; Peters GJ; Lankelma J; Pinedo HM
Cancer Res; 1984 Dec; 44(12 Pt 1):5928-33. PubMed ID: 6498850
[TBL] [Abstract][Full Text] [Related]
20. Protective, tumor-selective dual pathway activation of 5-fluoro-2'-deoxycytidine provided by tetrahydrouridine in mice bearing mammary adenocarcinoma-755.
Boothman DA; Briggle TV; Greer S
Cancer Res; 1987 May; 47(9):2344-53. PubMed ID: 2436761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
